Ramelteon NDC 80425-0593

NDC codes

FDA NDC Directory

Product NDC (as listed)80425-0593Labeler and product segments. Claims need a package NDC.

Product NDC at billing width80425-0593Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
80425-0593-1	80425059301	30 TABLET in 1 BOTTLE (80425-0593-1)Marketed from Jul 27, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ramelteon
Generic name (nonproprietary): ramelteon
Active ingredients: Ramelteon — 8 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Advanced Rx of Tennessee, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215243
Marketing start: Jul 27, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Melatonin Receptor Agonists (Mechanism)
Identifiers: Product ID 80425-0593_57b24374-73db-2c05-e063-6294a90aae55SPL ID 57b24374-73db-2c05-e063-6294a90aae55SPL set ID 57b24572-f601-b092-e063-6394a90afa53RxCUI 577348UNII 901AS54I69
Pharmacologic class: Melatonin Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N480425059301 followed by a unit qualifier and the quantity

Package 80425-0593-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 27, 2026.

Indications (excerpt from the label)

Ramelteon tablets are indicated for the treatment of insomnia characterized by difficulty with sleep onset. The clinical trials performed in support of efficacy were up to six months in duration. The final formal assessments of sleep latency were performed after two days of treatment during the crossover study (elderly only), at five weeks in the six week studies (adults and elderly), and at the end of the six month study (adults and elderly) [see Clinical Studies (14)]. Ramelteon tablet is indicated for the treatment of insomnia characterized by difficulty with sleep onset. (1)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215243

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215243
Product	Strength	Form · route	Labeler	Product NDC
Ramelteon	Ramelteon 8 mg/1	TabletOral	Sportpharm LLC	85766-251
Ramelteon	Ramelteon 8 mg/1	TabletOral	AvPAK	50268-822
Ramelteon	Ramelteon 8 mg/1	TabletOral	ASCLEMED USA INC.	87063-189
Ramelteon	Ramelteon 8 mg/1	TabletOral	Bryant Ranch Prepack	71335-2310
Ramelteon	Ramelteon 8 mg/1	TabletOral	Micro Labs Limited	42571-375